A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels

International Journal of Immunogenetics

Volumn 34, Issue 3, 2007, Pages 209-212

  Mahfoudh, W ^a   Bel Hadj Jrad, B ^a,c   Romdhane, A ^b   Chouchane, L ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b Regional Hospital of M'saken   (Tunisia)

^c UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTIGENS, CD95; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUNISIA;

EID: 34248561970     PISSN: 17443121     EISSN: 1744313X     Source Type: Journal    
DOI: 10.1111/j.1744-313X.2007.00676.x     Document Type: Article

References (26)

1. Ashkenazi, A. Dixit, V.M. (1999) Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology, 11, 255.
2. Bel Hadj Jrad, B., Mahfouth, W., Bouaouina, N., Gabbouj, S., Ben Ahmed, S., Ltaïef, M., Jalbout, M. Chouchane, L. (2006) A polymorphism in Fas gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Letters, 233, 21.
3. Cascino, I., Fiucci, G., Papoff, G. Ruberti, G. (1995) Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. Journal of Immunology, 154, 2706.
4. Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Brauer, M.J., Kiefer, M.C., Barr, P.J. Mountz, J.D. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 263, 1759.
5. Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middletn, L.A., Lin, A.Y., Strober, W. Lenardo, M.J. (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 81, 935.
6. Huang, Q.R., Morris, D. Manolios, N. (1997) Identification and characterization of polymorphisms in the promotor region of the human Apo-1/Fas (CD95) gene. Molecular Immunology, 34, 577.
7. Kanemitsu, S., Ihara, K., Saifddin, A., Otsuka, T., Takeuchi, T., Nagayama, J., Kuwano, M. Hara, T. (2002) A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with systemic lupus erythematosus. Journal of Rheumatology, 29, 1183.
8. Knipping, E., Debatin, K.M., Stricker, K., Heilig, B., Eder, A. Rammer, P.H. (1995) Identification of soluble APO-1 in supernatants of human B- and T-cell lines and incrased serum levels in B- and T-cell leukemias. Blood, 85, 1562.
9. Konno, R., Takano, T., Sato, S. Yajima, A. (2000) Serum soluble Fas level as a prognostic factor in patients with gynaecological malignancies. Clinical Cancer Research, 6, 3576.
10. Krams, S.M., Fox, C.K., Beatty, P.R., Cao, S., Villanueva, J.C., Esquivel, C.O. Martinez, O.M. (1998) Human hepatocytes produce an isoform of Fas that inhibits apoptosis. Transplantation, 65, 713.
11. Lai, H.C., Sytwu, H.K., Sun, C.A., Yu, M.H., Yu, C.P., Lui, H.S., Chang, C.C. Chu, T.Y. (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. International Journal of Cancer, 103, 221.
12. Lee, Y.H., Kim, Y.R., Ji, J.D., Sohn, J. Song, G.G. (2001) Fas promoter polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. Journal of Rheumatology, 28, 2008.
13. Lee, S.H., Shin, M.S., Park, W.S., Kim, H.S., Han, J.Y., Park, G.S. et al. (1999a) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene, 18, 3754.
14. Lee, S.H., Shin, M.S., Park, W.S., Kim, S.Y., Dong, S.M., Pi, J.H. et al. (1999b) Alteration of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Research, 59, 3068.
15. Nagata, S. (1999) Fas ligand-induced apoptosis. Annual Review of Genetics, 33, 29.
16. Nasi, M., Pinti, M., Bugarini, R., Troiano, L., Lugli, E., Bellodi, C. et al. (2005) Genetic polymorphism of Fas (CD95) and FasL (CD178) influence the rise in CD4+ T-cell count after antiretroviral therapy in drug-naïve HIV-positive patients. Immunogenetics, 57, 628.
17. Olerup, O. Zetterquist, H. (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 39, 225.
18. Owen-Schaub, L.B., Angelo, L.S., Radinsky, R., Ware, C.F., Gesner, T.G. Bartos, D.P. (1995) Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Letters, 94, 1.
19. Papoff, G., Cascino, I., Eramo, A., Starace, G., Lynch, D.H. Ruberti, G. (1996) An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. Journal of Immunology, 156, 4622.
20. Pinti, M., Troiano, L., Nasi, M., Moretti, L., Monterastelli, E., Mazzacani, A. et al. (2002) Genetic polymorphism of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differentiation, 9, 431.
21. Pirogov, A.V., Abbasova, S.G., Dyakova, N.A., Kushlinsy, N.E. Deichman, G.I. (2002) Change in the balance between membrane-bound and soluble forms of CD95 (Fas) during selection of tumor cells in vivo. Biochemistry (Mosc), 67, 240.
22. Pitti, R.M., Marsters, S.A., Lawrene, D.A., Roy, M., Kischkel, F.C., Dowd, P. et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (Lond.), 396, 699.
23. Proussakova, A.V., Rabaya, N.A., Moshnikova, A.B., Telegina, E.S., Turanov, A., Nanazashvili, M.G. Beletsky, I.P. (2003) Oligomerization of soluble Fas antigen induces its cytotoxicity. Journal of Biological Chemistry, 278, 36236.
24. Shin, M.S., Park, W.S., Kim, S.Y., Kang, S.J., Song, K.Y., Park, J.Y. et al. (1999) Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. American Journal of Pathology, 154, 1785.
25. Takayuki, U., Masakazu, T. Takeshi, T. (1999) Circulating soluble Fas concentration in breast cancer patients. Clinical Cancer Research, 5, 3529.
26. Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovaleno, A.V. Boldin, M.P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annual Review of Immunology, 17, 331.